<< Australian researchers advance bowel cancer detection | Cigarette smoking does not affect everyone in same way >>
Read in | English | Español | Français | Deutsch | Português | Italiano | 日本語 | 한국어 | 简体中文 | 繁體中文 | Nederlands | Русский | Svenska | Polski

Cancer vaccine efficacy enhanced using anti-diabetic drug Metformin

Published on June 4, 2009 at 8:13 PM · No Comments

After a vaccination or an infection, the human immune system remembers to keep protecting against invaders it has already encountered, with the aid of specialized B-cells and T-cells. Immunological memory has long been the subject of intense study, but the underlying cellular mechanisms regulating the generation and persistence of long-lived memory T cells remain largely undefined. Now, University of Pennsylvania School of Medicine researchers have found that a common anti-diabetic drug might enhance the effectiveness of vaccines. The findings are described this week in an advanced online publication of Nature.

In this study, an experimental preventive vaccine was made more efficacious by boosting numbers of cancer fighting T cells with the anti-diabetic drug metformin. This resulted in a larger population of memory immune cells that were able to fight off a tumor at a later time.

"We serendipitously discovered that the metabolizing, or burning, of fatty acids by T cells following the peak of infection is critical to establishing memory in those T cells," says senior author Yongwon Choi, PhD, Professor of Pathology and Laboratory Medicine. "As a consequence, we used the widely prescribed anti-diabetic drug metformin, which is known to operate on fatty-acid metabolism, to enhance this process."

"We have shown experimentally in mice that metformin increases T-cell memory as well as the ensuing protective immunity of an experimental anti-cancer vaccine," notes postdoctoral fellow and first author Erika Pearce, PhD.

"These findings were unanticipated, but are potentially extremely important and could revolutionize current strategies for both therapeutic and prophylactic vaccines," says Choi.

The lab developed mice deficient in TRAF6, a protein important in the immune response. They found that CD8 T cells deficient in TRAF6 mount an initial response, meaning they are able to proliferate into an army of so-called effector cells that can clear infection. However, TRAF6-deficient CD8 T cells do not develop into a population of memory cells that can recall a particular infectious agent when the body encounters it a second time.

Using microarray analysis and a program that searches protein pathways, the team compared the gene expression profiles of TRAF6-deficient cells and cells with TRAF6 to see what stood out. "We discovered differences in genes that regulate fatty acid metabolism," says Pearce. Fatty acids can be broken down for energy and the microarray analyses revealed that TRAF6-deficient CD8 T cells exhibit altered expression of genes that regulate this process.

Comments
The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.



  Country flag

biuquote
  • Comment
  • Preview
Loading